These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 26064876)

  • 61. Systemic γ-sarcoglycan AAV gene transfer results in dose-dependent correction of muscle deficits in the LGMD 2C/R5 mouse model.
    Seo YE; Baine SH; Kempton AN; Rogers OC; Lewis S; Adegboye K; Haile A; Griffin DA; Peterson EL; Pozsgai ER; Potter RA; Rodino-Klapac LR
    Mol Ther Methods Clin Dev; 2023 Mar; 28():284-299. PubMed ID: 36816759
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The super-healing MRL strain promotes muscle growth in muscular dystrophy through a regenerative extracellular matrix.
    O'Brien JG; Willis AB; Long AM; Kwon J; Lee G; Li FW; Page PG; Vo AH; Hadhazy M; Spencer MJ; Crosbie RH; Demonbreun AR; McNally EM
    JCI Insight; 2024 Jan; 9(3):. PubMed ID: 38175727
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Assessment of ventricular function in mouse models of muscular dystrophy: a comparison of MRI with conductance catheter.
    Blain AM; Greally E; Laval SH; Blamire AM; MacGowan GA; Straub VW
    Neuromuscul Disord; 2015 Jan; 25(1):24-31. PubMed ID: 25454734
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Exploiting the full power of temporal gene expression profiling through a new statistical test: application to the analysis of muscular dystrophy data.
    Vinciotti V; Liu X; Turk R; de Meijer EJ; 't Hoen PA
    BMC Bioinformatics; 2006 Apr; 7():183. PubMed ID: 16584545
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Muscle proteins and muscular dystrophy.
    Slater CR
    Curr Opin Cell Biol; 1989 Feb; 1(1):110-4. PubMed ID: 2698203
    [No Abstract]   [Full Text] [Related]  

  • 66. Minimal Consequences of CMAH and DBA/2 Backgrounds on a FKRP Deficient Model.
    Vaubourg C; Gicquel E; Richard I; Lostal W; Bellec J
    J Neuromuscul Dis; 2021; 8(5):785-793. PubMed ID: 32925084
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Circulating miRNAs are generic and versatile therapeutic monitoring biomarkers in muscular dystrophies.
    Israeli D; Poupiot J; Amor F; Charton K; Lostal W; Jeanson-Leh L; Richard I
    Sci Rep; 2016 Jun; 6():28097. PubMed ID: 27323895
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Genetic evidence in the mouse solidifies the calcium hypothesis of myofiber death in muscular dystrophy.
    Burr AR; Molkentin JD
    Cell Death Differ; 2015 Sep; 22(9):1402-12. PubMed ID: 26088163
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Rather mild phenotype in a patient with homozygous null mutations in the alpha-sarcoglycan gene.
    Ramelli GP; Joncourt F; Gasperini M; Tonin P; Burgunder JM
    Swiss Med Wkly; 2006 Feb; 136(5-6):96-7. PubMed ID: 16633953
    [No Abstract]   [Full Text] [Related]  

  • 70. Genes and brains, molecular medicine and neuropathology.
    Laing N
    Trends Mol Med; 2001 Jan; 7(1):6-7. PubMed ID: 11427991
    [No Abstract]   [Full Text] [Related]  

  • 71. Therapy of hereditary mouse muscular dystrophy with coenzyme Q7.
    Scholler J; Jones D; Littarru GP; Folkers K
    Biochem Biophys Res Commun; 1970 Dec; 41(5):1298-305. PubMed ID: 5483632
    [No Abstract]   [Full Text] [Related]  

  • 72. Mouse models for muscular dystrophies: an overview.
    van Putten M; Lloyd EM; de Greef JC; Raz V; Willmann R; Grounds MD
    Dis Model Mech; 2020 Feb; 13(2):. PubMed ID: 32224495
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Murine genetic models of human disease.
    Clarke AR
    Curr Opin Genet Dev; 1994 Jun; 4(3):453-60. PubMed ID: 7919924
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Xenograft: a powerful tool! Protocol to better follow the evolution of muscular dystrophy].
    Mornet D
    Med Sci (Paris); 2019 Nov; 35 Hors série n° 2():47-48. PubMed ID: 31859633
    [No Abstract]   [Full Text] [Related]  

  • 75. Simultaneous Pathoproteomic Evaluation of the Dystrophin-Glycoprotein Complex and Secondary Changes in the mdx-4cv Mouse Model of Duchenne Muscular Dystrophy.
    Murphy S; Henry M; Meleady P; Zweyer M; Mundegar RR; Swandulla D; Ohlendieck K
    Biology (Basel); 2015 Jun; 4(2):397-423. PubMed ID: 26067837
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The Dystrophin Complex: Structure, Function, and Implications for Therapy.
    Gao QQ; McNally EM
    Compr Physiol; 2015 Jul; 5(3):1223-39. PubMed ID: 26140716
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Implications for Cardiac Function Following Rescue of the Dystrophic Diaphragm in a Mouse Model of Duchenne Muscular Dystrophy.
    Betts CA; Saleh AF; Carr CA; Muses S; Wells KE; Hammond SM; Godfrey C; McClorey G; Woffindale C; Clarke K; Wells DJ; Gait MJ; Wood MJ
    Sci Rep; 2015 Jun; 5():11632. PubMed ID: 26113184
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Costamere proteins and their involvement in myopathic processes.
    Jaka O; Casas-Fraile L; López de Munain A; Sáenz A
    Expert Rev Mol Med; 2015 Jun; 17():e12. PubMed ID: 26088790
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Low-Level Laser Therapy (LLLT) in Dystrophin-Deficient Muscle Cells: Effects on Regeneration Capacity, Inflammation Response and Oxidative Stress.
    Macedo AB; Moraes LH; Mizobuti DS; Fogaça AR; Moraes Fdos S; Hermes Tde A; Pertille A; Minatel E
    PLoS One; 2015; 10(6):e0128567. PubMed ID: 26083527
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Spatio-Temporal Differences in Dystrophin Dynamics at mRNA and Protein Levels Revealed by a Novel FlipTrap Line.
    Ruf-Zamojski F; Trivedi V; Fraser SE; Trinh le A
    PLoS One; 2015; 10(6):e0128944. PubMed ID: 26083378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.